Submitted by Anonymous (not verified) on 18 October 2023 - 18:45
Human medicines European public assessment report (EPAR): Briumvi, ublituximab, Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Date of authorisation: 31/05/2023, Revision: 01, Status: Authorised
Source: